Mazen Almehmadi, Khalid Alzahrani, Magdi M.Salih, Abdulaziz Alsharif, Naif Alsiwiehri, Alaa Shafie, Abdulraheem A. Almalki, Haytham Dahlawi, Ayman Al-hazmi, Ashwaq Al-khalidi, Njood Al-ghoraibi, Wedad Al-osaimi, Ashwaq M Altahli, Mustafa Halawi, Abdulrhman M. Almehmadi

Abstract

Thyroid-function-test is a routine laboratory exam performed in many patients; the test usually includes TSH, free-T3 (FT3), and free-T4 (FT4). Levels of these hormones can provide essential reading to evaluate thyroid gland functions. 92 patients were recruited into this study, mostly females diagnosed either with female-genital tract cancer or breast cancer. Levels of TSH, FT3, and FT4 were evaluated by ROCHE COBAS ® platform e501; TSH normal levels are 0.51 to 4.1 μIU/ml, FT3 between 3.6 to 6.9 pmol\L, and FT4 between 12.3 to 20.2 pmol\L. The results of this study indicate different levels of TSH, FT3, and FT4 from most cancer patients, and hypothyroidism in gastrointestinal tract cancer patients. Also, premenopausal females with cancer have shown signs of hypothyroidism. To conclude, normal levels of TSH, FT3, and FT4 were detected in most of this study patients, hypothyroidism was detected in the gastrointestinal tract and part of pre and post-menopause female cancer patients.